Clinical Trial Record

Return to Clinical Trials

IORT Followed by CCRT or SBRT for Locally Advanced Pancreatic Cancer


2016-02


2018-02


2019-02


70

Study Overview

IORT Followed by CCRT or SBRT for Locally Advanced Pancreatic Cancer

The purpose of this study is to find the best model of combination of intraoperative radiotherapy(IORT) and postoperative radiochemotherapy for pancreatic cancer.

The trial is funded by Cancer Foundation of China. The trial is prepared to be registered on the clinicaltrail.gov. Quality assurance plan: every participant is enrolled or excluded by two practiced investigators. And two investigators participated in all steps of the trail, including the record of the data, and the investigators will compare the data. If the data is consistent, the investigators would record the data; if not, the data would be checked and decided by the two investigators. All the steps and data are site monitored and audited by the workers of research and financial department of National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences. Data check: the investigators compare data entered into the registry against predefined rules for range or consistency with other data fields in the registry. Source data verification to assess the accuracy, completeness, or representativeness of registry data by comparing the data to external data sources, including medical records and electronic case report forms. Data dictionary that contains detailed descriptions of each variable used by the registry, including the source of the variable, coding information, and normal ranges if relevant. Standard Operating Procedures to address registry operations and analysis activities, such as participants recruitment, data collection, data management, data analysis, reporting for adverse events, and change management. All registry operations would be done according to specific steps, and by two practiced investigators. Sample size assessment to specify the number of participants or participant years necessary to demonstrate an effect. According to the formula to differ advantages and disadvantages, the investigators need at least 70 participants to take part in the trail. The investigators can recruit about 35 participants every year according to previous experiences, so the investigators should recruit at least for two years. Plan for missing data: the investigators would collect as much data as possible, and the investigators exclude the participants who cannot cooperate on recruitment. And the investigators manage situations according to statistical principles where variables are reported as missing, unavailable, "non-reported," uninterpretable, or considered missing because of data inconsistency or out-of-range results. Statistical analysis plan: Kaplan-Meier method would be used to analyze the difference of survival time between the two groups, and the local control rate of the two groups would be compared by chi square test. Statistical analyses would be performed by using IBM SPSS Statistics(version 20; IBM, Chicago, USA). The level of significance is defined as P < 0.05.

  • Pancreatic Cancer
  • RADIATION: Concurrent chemoradiotherapy(CCRT)
  • RADIATION: Stereotactic Radiotherapy(SBRT)
  • DRUG: S-1
  • LC2015L11

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2016-04-07  

N/A  

2017-04-09  

2016-04-07  

N/A  

2017-04-11  

2016-04-12  

N/A  

2017-04  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment


Allocation:
Randomized


Interventional Model:
Parallel


Masking:
Single


Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: Concurrent chemoradiotherapy(CCRT) Group

Concurrent chemoradiotherapy(CCRT) (Total dose: 46 Gy; Single dose: 2 Gy; Frequency: 23; Gemcitabine(GEM), 300 mg/m2 weekly); Followed by taking S-1 orally (40 mg/m2, bid on Day 1-28, Q42d)

RADIATION: Concurrent chemoradiotherapy(CCRT)

  • Radiation and take gemcitabine(GEM)

DRUG: S-1

  • Taking S-1 orally after radiation
EXPERIMENTAL: Stereotactic Radiotherapy(SBRT) Group

Stereotactic Radiotherapy(SBRT) (Total dose: 45 Gy; Single dose: 3 Gy; Frequency: 15) Followed by taking S-1 orally (40 mg/m2, bid on Day 1-28, Q42d)

RADIATION: Stereotactic Radiotherapy(SBRT)

  • Stereotactic Radiotherapy(SBRT) (total dose: 45 Gy; single dose: 3 Gy; Frequency:15)

DRUG: S-1

  • Taking S-1 orally after radiation
Primary Outcome MeasuresMeasure DescriptionTime Frame
Overal survivalOS2 years
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Disease-specific survivalDSS2 years
Progression-free survivalPFS2 years
Local control rateLCR2 years

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Yingtai Chen, PhD

Phone Number: +8618600258827

Email: yingtai.chen@hotmail.com

Study Contact Backup

Name: Shuisheng Zhang, M.D.

Phone Number: +8618001302322

Email: thelifeofwater@126.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:

  • Diagnosed as locally advanced pancreatic cancer.
  • Cannot be treated by surgical resection.

  • Exclusion Criteria:

  • Treated by chemotherapy or radiotherapy before.
  • With distant organ metastasis.
  • Cannot tolerate surgery (Intraoperative radiotherapy)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.


    • PRINCIPAL_INVESTIGATOR: Chengfeng Wang, B.A., Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available